Walter Newman BA, PhD

Dr. Newman, a graduate of Columbia University's undergraduate and graduate programs with a degree in immunology, led drug discovery at LeukoSite and Critical Therapeutics where he helped bring multiple antibody and small molecule candidates into clinical trials. LeukoSite's efforts resulted in two approved monoclonal therapeutics, alemtuzumab and vedolizumab. In addition he was the founding CSO at Proteostasis Therapeutics. Prior to that, Dr. Newman had senior roles in drug discovery at both Ortho Pharmaceuticals and Otsuka America Pharmaceuticals, subsequent to an academic career at the Fred Hutchinson Cancer Research Center. He has co-authored over eighty scientific articles in peer-reviewed journals.